Revisiting old drugs as novel agents for retinoblastoma: In vitro and in vivo antitumor activity of cardenolides

Investigative Ophthalmology and Visual Science

Volumn 50, Issue 7, 2009, Pages 3065-3073

  Antczak, Christophe ^a   Kloepping, Carolyn ^a   Radu, Constantin ^a   Genski, Thorsten ^b   Müller Kuhrt, Lutz ^b   Siems, Karsten ^b   de Stanchina, Elisa ^c   Abramson, David H ^d   Djaballah, Hakim ^a  

^a High Throughput Screening Core Facility   (United States)

^b ANALYTICON DISCOVERY GMBH   (Germany)

^c Molecular Pharmacology and Chemistry Program   (United States)

^d MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CALCITRIOL; CARBOPLATIN; CARDENOLIDE DERIVATIVE; CARDIAC GLYCOSIDE; CASPASE 3; CISPLATIN; DIGOXIGENIN; DIGOXIN; ETOPOSIDE; GAMBOGIC ACID; NERIIFOLLIN; NIGERICIN; NUTLIN 3; OUABAIN; PERUVOSIDE; PHENYLMERCURIC ACETATE; PRIMAQUINE; PROPACHLOR; PYRITHIONE ZINC; UNCLASSIFIED DRUG; VINCRISTINE; ANTINEOPLASTIC AGENT; CARDENOLIDE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; CANCER CELL CULTURE; CONTINUOUS INFUSION; CONTROLLED STUDY; CYTOTOXICITY; DRUG APPROVAL; DRUG DOSE COMPARISON; DRUG POTENCY; DRUG STRUCTURE; ENZYME ACTIVATION; FOOD AND DRUG ADMINISTRATION; HIGH THROUGHPUT SCREENING; HUMAN; HUMAN CELL; IMMUNOFLUORESCENCE; IN VITRO STUDY; IN VIVO STUDY; MALE; MOUSE; NONHUMAN; OSMOTIC MINIPUMP; PRIORITY JOURNAL; RETINOBLASTOMA; TUMOR REGRESSION; TUMOR VOLUME; TUMOR XENOGRAFT; ANIMAL; DOSE RESPONSE; DRUG EFFECT; DRUG RESISTANCE; DRUG SCREENING; ENZYMOLOGY; INSTITUTE FOR CANCER RESEARCH MOUSE; METABOLISM; MOUSE MUTANT; PATHOLOGY; RETINA TUMOR; TUMOR CELL CULTURE;

ANIMALS; ANTINEOPLASTIC AGENTS; APOPTOSIS; CARDENOLIDES; CASPASE 3; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG RESISTANCE, NEOPLASM; DRUG SCREENING ASSAYS, ANTITUMOR; HUMANS; MALE; MICE; MICE, INBRED ICR; MICE, SCID; RETINAL NEOPLASMS; RETINOBLASTOMA; TUMOR CELLS, CULTURED; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 67649992705     PISSN: 01460404     EISSN: 15525783     Source Type: Journal    
DOI: 10.1167/iovs.08-3158     Document Type: Article

References (37)

1. Abramson DH. Retinoblastoma in the 20th century: past success and future challenges: the Weisenfeld Lecture. Invest Ophthalmol Vis Sci. 2005;46:2683-2691.
2. De Potter P. Current treatment of retinoblastoma. Curr Opin Ophthalmol. 2002;13:331-336.
3. Brichard B, De Bruycker JJ, De Potter P, Neven B, Vermylen C, Cornu G. Combined chemotherapy and local treatment in the management of intraocular retinoblastoma. Med Pediatr Oncol. 2002;38:411-415.
4. Benz MS, Scott IU, Murray TG, Kramer D, Toledano S. Complications of systemic chemotherapy as treatment of retinoblastoma. Arch Ophthalmol. 2000;118:577-578.
5. Beck MN, Balmer A, Dessing C, Pica A, Munier F. First-line chemotherapy with local treatment can prevent external-beam irradiation and enucleation in low-stage intraocular retinoblastoma. J Clin Oncol. 2000;18:2881-2887.
6. Friedman DL, Himelstein B, Shields CL, et al. Chemoreduction and local ophthalmic therapy for intraocular retinoblastoma. J Clin Oncol. 2000;18:12-17.
7. Rizzuti AE, Dunkel IJ, Abramson DH. The adverse events of chemotherapy for retinoblastoma: what are they?-do we know? Arch Ophthalmol. 2008;126:862-865.
8. Klein G, Michaelis J, Spix C, et al. Second malignant neoplasms after treatment of childhood cancer. Eur J Cancer. 2003;39:808-817.
9. Nishimura S, Sato T, Ueda H, Ueda K. Acute myeloblastic leukemia as a second malignancy in a patient with hereditary retinoblastoma. J Clin Oncol. 2001;19:4182-4183.
10. Chantada G, Fandino A, Casak S, Manzitti J, Raslawski E, Schvartzman E. Treatment of overt extraocular retinoblastoma. Med Pediatr Oncol. 2003;40:158-161.
11. Albert DM, Kumar A, Strugnell SA, et al. Effectiveness of vitamin D analogues in treating large tumors and during prolonged use in murine retinoblastoma models. Arch Ophthalmol. 2004;122: 1357-1362.
12. Albert DM, Plum LA, Yang W, et al. Responsiveness of human retinoblastoma and neuroblastoma models to a non-calcemic 19-nor vitamin D analog. J Steroid Biochem Mol Biol. 2005;97:165-172.
13. Audo I, Darjatmoko SR, Schlamp CL, et al. Vitamin D analogues increase p53, p21, and apoptosis in a xenograft model of human retinoblastoma. Invest Ophthalmol Vis Sci. 2003;44:4192-4199.
14. Wagner N, Wagner KD, Schley G, Badiali L, Theres H, Scholz H. 1,25-dihydroxyvitamin D3-induced apoptosis of retinoblastoma cells is associated with reciprocal changes of Bcl-2 and bax. Exp Eye Res. 2003;77:1-9.
15. Vassilev LT, Vu BT, Graves B, et al. In vivo activation of the p53 pathway by small-molecule antagonists of MDM2. Science. 2004; 303:844-848.
16. Laurie NA, Donovan SL, Shih CS, et al. Inactivation of the p53 pathway in retinoblastoma. Nature. 2006;444:61-66.
17. Elison JR, Cobrinik D, Claros N, Abramson DH, Lee TC. Small molecule inhibition of HDM2 leads to p53-mediated cell death in retinoblastoma cells. Arch Ophthalmol. 2006;124:1269-1275.
18. Abramson DH, Dunkel IJ, Brodie SE, Kim JW, Gobin YP. A phase I/II study of direct intra-arterial (ophthalmic artery) chemotherapy with melphalan for intraocular retinoblastoma initial results. Ophthalmology. 2008;115:1398-1404, 1404 e1391.
19. Prestwick Chemical, Inc., Illkirch, France. http://www.prestwickchemical.fr/.
20. Microsource Discovery Systems, Inc., Gaylordsville, CT. http://www.msdiscovery.com/.
21. Desbordes SC, Placantonakis DG, Ciro A, et al. High-throughput screening assay for the identification of compounds regulating self-renewal and differentiation in human embryonic stem cells. Cell Stem Cell. 2008;2:602-612.
22. AnalytiCon Discovery GmbH, http://www.ac-discovery.com/.
23. Ahmed SA, Gogal RM, Jr, Walsh JE. A new rapid and simple non-radioactive assay to monitor and determine the proliferation of lymphocytes: an alternative to [3H]thymidine incorporation assay. J Immunol Methods. 1994;170:211-224.
24. Shum D, Radu C, Kim E, et al. A high density assay format for the detection of novel cytotoxic agents in large chemical libraries. J Enzyme Inhib Med Chem. 2008;23:931-945.
25. Reid TW, Albert DM, Rabson AS, et al. Characteristics of an established cell line of retinoblastoma. J Natl Cancer Inst. 1974;53:347-360.
26. Fournier GA, Sang DN, Albert DM, Craft JL. Electron microscopy and HLA expression of a new cell line of retinoblastoma. Invest Ophthalmol Vis Sci. 1987;28:690-699.
27. Antczak C, Shum D, Escobar S, et al. High-throughput identification of inhibitors of human mitochondrial peptide deformylase. J Biomol Screen. 2007;12:521-535.
28. Schoner W, Scheiner-Bobis G. Endogenous and exogenous cardiac glycosides: their roles in hypertension, salt metabolism, and cell growth. Am J Physiol Cell Physiol. 2007;293:C509-536.
29. Rahimtoola SH, Tak T. The use of digitalis in heart failure. Curr Probl Cardiol. 1996;21:781-853.
30. Newman RA, Yang P, Pawlus AD, Block KI. Cardiac glycosides as novel cancer therapeutic agents. Mol Interv. 2008;8:36-49.
31. Idziorek T, Estaquier J, De Bels F, Ameisen JC. YOPRO-1 permits cytofluorometric analysis of programmed cell death (apoptosis) without interfering with cell viability. J Immunol Methods. 1995; 85:249-258.
32. Conway RM, Madigan MC, Billson FA, Penfold PL. Vincristine-and cisplatin-induced apoptosis in human retinoblastoma. Potentiation by sodium butyrate. Eur J Cancer. 1998;34:1741-1748.
33. Giuliano M, Lauricella M, Vassallo E, Carabillo M, Vento R, Tesoriere G. Induction of apoptosis in human retinoblastoma cells by topoisomerase inhibitors. Invest Ophthalmol Vis Sci. 1998;39: 1300-1311.
34. Eng C, Li FP, Abramson DH, et al. Mortality from second tumors among long-term survivors of retinoblastoma. J Natl Cancer Inst. 1993;85:1121-1128.
35. Lopez-Lazaro M, Pastor N, Azrak SS, Ayuso MJ, Austin CA, Cortes F. Digitoxin inhibits the growth of cancer cell lines at concentrations commonly found in cardiac patients. J Nat Prod. 2005;68:1642-1645.
36. Stenkvist B, Bengtsson E, Eriksson O, Holmquist J, Nordin B, Westman-Naeser S. Cardiac glycosides and breast cancer. Lancet. 1979;1:563.
37. Stenkvist B. Is digitalis a therapy for breast carcinoma?. Oncol Rep. 1999;6:493-496.